A study was carried out in a hemizygous double mutant PS1/APP mice model of AD where the animals received orally a daily dose of 250 mg/kg of BM15.766 [(4-(2-[1-(4-chlorocinnamyl)piperazine-4-yl]ethyl]benzoic acid)], a drug that reduces cholesterol levels by inhibiting the enzyme, 7-dehydrocholesterol-D7-reductase, that catalyses the last step of cholesterol biosynthesis. The gene discussed is APP; the disease is Alzheimer disease.